|
業務類別
|
Biotechnology |
|
業務概覽
|
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mentalfatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders. |
| 公司地址
| 343 Allerton Avenue, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 577-3600 |
| 傳真號碼
| +1 888 482-2602 |
| 公司網頁
| https://www.vistagen.com |
| 員工數量
| 41 |
| Mr. Shawn K. Singh, J.D. |
President, Chief Executive Officer and Director |
美元 650.00K |
31/07/2026 |
| Mr. Nick B. Tressler |
Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 150.00K |
31/07/2026 |
| Mr. Reid G. Adler, J.D. |
Chief Legal Officer |
美元 450.00K |
31/07/2026 |
| Mr. Joshua S. Prince, M.B.A. |
Chief Operating Officer |
美元 415.00K |
31/07/2026 |
| Ms. Elissa S. Cote |
Chief Corporate Development and Strategy Officer |
美元 320.68K |
31/07/2026 |
| Dr. Angel S. Angelov, M.B.A.,M.D. |
Chief Medical Officer |
-- |
19/05/2026 |
|
|
| Mr. Shawn K. Singh, J.D. |
President, Chief Executive Officer and Director |
31/07/2026 |
| Mr. Jon S. Saxe, J.D.,L.L.M. |
Chairman of the Board |
31/07/2026 |
| Ms. Ann M. Cunningham, M.B.A. |
Independent Director |
31/07/2026 |
| Dr. Joanne Curley, PhD |
Independent Director |
17/06/2026 |
| Ms. Margaret M. FitzPatrick, M.A. |
Independent Director |
17/06/2026 |
| Mr. Douglas J. Williamson |
Independent Director |
31/07/2026 |
|
|
|
|
